Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial
- 1 April 2016
- journal article
- research article
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 4 (4) , 309-317
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 30 references indexed in Scilit:
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionKidney International, 2011
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in DiabetesJournal of the American Society of Nephrology, 2009
- Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and AlbuminuriaDiabetes Care, 2009
- Lowering Blood Pressure Reduces Renal Events in Type 2 DiabetesJournal of the American Society of Nephrology, 2009
- Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 DiabetesDiabetes Care, 2007
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Retarding progression of chronic renal disease: The neglected issue of residual proteinuriaKidney International, 2003
- Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseaseKidney International, 2001
- A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal functionKidney International, 1997
- THE PREPARATION, PURIFICATION, AND AMINO ACID SEQUENCE OF A POLYPEPTIDE RENIN SUBSTRATEJournal of Experimental Medicine, 1957